Navigation Links
HistoRx Names Kate Adams Vice President, Diagnostics Marketing and Retains Steve Chubb as Strategic Advisor

--New appointments continue to strengthen diagnostics product development business--

NEW HAVEN, Conn., Dec. 17 /PRNewswire/ -- HistoRx, Inc., announced today that it has appointed Kathleen Q. Adams to the newly created position of Vice President, Diagnostics Marketing and has retained Stephen D. Chubb as a Strategic Advisor to the company.

Ms. Adams brings to HistoRx 20 years of marketing experience in the diagnostics and pharmaceuticals industries. Before joining HistoRx, she was Marketing Director of New Technology Planning & Research for Quest Diagnostics, following her appointment there as Director of Oncology Marketing. Previously, Ms. Adams held various positions in product management at Parke-Davis Pharmaceuticals, Schering-Plough, and Genetics Institute (now a division of Wyeth). She holds an M.B.A. from the Yale School of Management.

"I am excited to join HistoRx at this pivotal point in its development and ready to lead the company's marketing efforts," said Ms. Adams. "Within the next few years, we expect HistoRx's diagnostic products will provide oncologists and their patients with important new tools for making key treatment decisions in a variety of cancer indications."

Steve Chubb is a seasoned executive with more than 30 years of experience in the medical products and biotechnology industries. In his role as Strategic Advisor, he will assist HistoRx in identifying and assessing business development initiatives and opportunities. Most recently, Mr. Chubb was Founder, Chairman, and CEO of Matritech, Inc., a cancer diagnostics company that he created, took public, and sold to a world-leading point-of-care diagnostics company. Prior to that, he held the positions of CEO and Chairman of T Cell Sciences, Inc. and CEO and Chairman of Cytogen Corp. Mr. Chubb holds an M.B.A. from the Kellogg School of Management at Northwestern University and is a graduate of the U.S. Naval Academy.

"The HistoRx technologies for measuring protein in tissue in a quantitative, localized, and reproducible way represent the near-term future of cancer diagnostics, and the AQUA(R) system enables HistoRx to do this in a way no other company can," said Mr. Chubb. "I am pleased to help the company realize its substantial commercial potential."

Rana K. Gupta, CEO of HistoRx, commented, "We are very pleased to have Kate and Steve join the company. Their combination of diagnostics industry expertise and general management experience will be of tremendous benefit to the HistoRx management team. With Kate's and Steve's leadership, the company is well positioned for future growth and success."

About HistoRx (

HistoRx, Inc. is a leading developer of tissue-based theranostic solutions to advance individualized patient care. The company's products and services are based on proprietary AQUA(R) tissue biomarker analysis technology. AQUA(R) is the only platform capable of precisely measuring protein biomarker concentration with subcellular resolution in tissue sections, enabling fully objective, standardized, reproducible, and automated analysis to guide targeted drug development and therapeutic decisionmaking. HistoRx helps biopharmaceutical companies advance their product pipelines by generating valuable new insights into the safety and effectiveness of targeted therapeutics in development for cancer and other diseases. These partnerships provide the foundation for HistoRx to develop proprietary companion diagnostic tests that HistoRx will co-market with its partners' targeted therapeutics. HistoRx also pursues internal programs to develop a pipeline of proprietary standard-of-care diagnostic products targeting improved treatment decisionmaking and patient outcomes in cancer care.

    Thomas Gerson
    Chief Financial Officer
    (203) 498-7500

SOURCE HistoRx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. ResMed Names Kieran Gallahue as Chief Executive Officer, Effective January 1, 2008.
2. Mediware Names Thomas K. Mann Chief Executive Officer
3. Cleveland-based Health Care Tech Company Within3 Names New CEO
4. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
5. Patient Safety Authority Board of Directors Names Infection Advisory Panel
6. Hooper Holmes Names Chris Behling President of Health & Wellness Division
7. MDMA Names New Director of Federal Affairs
8. Milestone Scientific Names Robert Presutti New Vice President of Sales and Marketing
9. Acuo Technologies(R) Names Mike Dolan Vice President of Sales
10. MAKO Surgical Corp. Names Frederic H. Moll, M.D. to Board of Directors
11. Arthur M. Blank Family Foundation Names Susan Bertonaschi Program Officer, Better Beginnings
Post Your Comments:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned by ... to enhance the health of felines. The formula is all-natural and is made from ... the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... 25, 2016 , ... Austin residents seeking Mohs surgery services, can now turn ... to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization ... selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction ...
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Research and Markets has announced the addition ... - Forecast to 2022" report to their offering. ... to date financial data derived from varied research sources to ... potential impact on the market during the next five years, ... of sub markets, regional and country level analysis. The report ...
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas ... Brasil as the company,s second affiliate in Latin America . ... ... of Astellas Farma Colombia ... ...
Breaking Medicine Technology: